Testing new drugs to improve diuretic effectiveness in heart and kidney patients
Official title: Preclinical validation of Kir4.1/5.1 inhibitors for overcoming diuretic resistance
Funded at Vanderbilt University Medical Center · NIH-10904756 · Data updated 2026-11-12
This study is looking at a new way to help people with heart failure, kidney disease, or liver disease who struggle to get rid of extra fluid, by testing a special treatment that could make their diuretic medications work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | August 15, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $458,819 |
| NIH project number | 5R01DK137302-02 |
| Project ID | NIH-10904756 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with congestive heart failure, chronic kidney disease, or chronic liver disease who experience diuretic resistance.
✕Less likely to help
Patients who do not have fluid overload issues or those with conditions unrelated to diuretic resistance may not benefit from this research.
What this research studies
This research focuses on addressing diuretic resistance, a common issue in patients with congestive heart failure, chronic kidney disease, and liver disease. It investigates the use of novel Kir4.1/5.1 inhibitors to enhance the effectiveness of diuretics, which are medications used to remove excess fluid from the body. By targeting specific channels in the kidneys, the research aims to improve fluid management in patients who do not respond well to standard diuretics. The approach involves preclinical validation, meaning it will be tested in laboratory settings before any potential clinical application.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from fluid overload due to heart and kidney conditions.
How similar studies have gone: While the approach of using Kir4.1/5.1 inhibitors is relatively novel, there is growing interest in developing new diuretics to overcome resistance, indicating potential for success.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Denton, Jerod S. — Vanderbilt University Medical Center
- Study coordinator: Denton, Jerod S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.